Publications en collaboration avec des chercheurs de Hospital General Universitario Gregorio Marañón (9)

2022

  1. First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers

    Cancer Chemotherapy and Pharmacology, Vol. 89, Núm. 4, pp. 499-514

2021

  1. Trends and outcome of neoadjuvant treatment for rectal cancer: A retrospective analysis and critical assessment of a 10-year prospective national registry on behalf of the Spanish Rectal Cancer Project

    European Journal of Surgical Oncology, Vol. 47, Núm. 2, pp. 276-284

2020

  1. The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)

    Oncologist, Vol. 25, Núm. 3, pp. e451-e459

2019

  1. Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer (Scientific Reports, (2019), 9, 1, (2589), 10.1038/s41598-019-39291-2)

    Scientific Reports

  2. Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

    Scientific Reports, Vol. 9, Núm. 1

  3. Phase I dose-escalation of trifluridine/tipiracil in combination with oxaliplatin in patients with metastatic colorectal cancer

    European Journal of Cancer, Vol. 112, pp. 12-19

2017

  1. Phase Ib study of lumretuzumab plus cetuximab or erlotinib in solid tumor patients and evaluation of HER3 and heregulin as potential biomarkers of clinical activity

    Clinical Cancer Research, Vol. 23, Núm. 18, pp. 5406-5415

2011

  1. Treatment recommendations for metastatic colorectal cancer

    Clinical and Translational Oncology, Vol. 13, Núm. 3, pp. 162-178

2010

  1. SEOM clinical guidelines for the treatment of advanced colorectal cancer

    Clinical and Translational Oncology, Vol. 12, Núm. 11, pp. 729-734